Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65


Annexin-A5 resistance and non-criteria antibodies for the diagnosis of seronegative antiphospholipid syndrome.

Ferreira TG, Delhommeau F, Johanet C, Gerotziafas G, Bornes M, Cohen J, Kayem G, Fain O, Planche V, Mékinian A.

Clin Rheumatol. 2020 Jan 10. doi: 10.1007/s10067-019-04915-5. [Epub ahead of print]


Fractionated gemtuzumab ozogamicin in association with high dose chemotherapy: a bridge to allogeneic stem cell transplantation in refractory and relapsed acute myeloid leukemia.

Debureaux PE, Labopin M, Mamez AC, Lapusan S, Isnard F, Adaeva R, Bonnin A, Hirsch P, Delhommeau F, Battipaglia G, Duléry R, Malard F, Vekhoff A, Mohty M, Legrand O, Brissot E.

Bone Marrow Transplant. 2019 Sep 25. doi: 10.1038/s41409-019-0690-2. [Epub ahead of print]


Targeted molecular characterization shows differences between primary and secondary myelofibrosis.

Courtier F, Garnier S, Carbuccia N, Guille A, Adélaide J, Chaffanet M, Hirsch P, Paz DL, Slama B, Vey N, Ugo V, Delhommeau F, Rey J, Birnbaum D, Murati A.

Genes Chromosomes Cancer. 2019 Jul 24. doi: 10.1002/gcc.22789. [Epub ahead of print]


Proportion of Cytotoxic Peripheral Blood Natural Killer Cells and T-Cell Large Granular Lymphocytes in Recurrent Miscarriage and Repeated Implantation Failure: Case-Control Study and Meta-analysis.

Kolanska K, Suner L, Cohen J, Ben Kraiem Y, Placais L, Fain O, Bornes M, Selleret L, Delhommeau F, Feger F, Mathieu d'Argent E, Darai E, Chabbert-Buffet N, Antoine JM, Kayem G, Mekinian A.

Arch Immunol Ther Exp (Warsz). 2019 Aug;67(4):225-236. doi: 10.1007/s00005-019-00546-5. Epub 2019 May 30. Review.


Chronic myelomonocytic leukaemia associated with large- and medium-sized arteries vasculitis of the small bowel.

Martin de Frémont G, Gobert D, Hor T, Fabiani B, Gimenez de Mestral S, Delhommeau F, Fain O, Mekinian A.

Rheumatology (Oxford). 2019 Oct 1;58(10):1882-1883. doi: 10.1093/rheumatology/kez187. No abstract available.


Systemic Dysfunction of Osteoblast Differentiation in Adipose-Derived Stem Cells from Patients with Multiple Myeloma.

Béréziat V, Mazurier C, Auclair M, Ferrand N, Jolly S, Marie T, Kobari L, Toillon I, Delhommeau F, Fève B, Larsen AK, Sabbah M, Garderet L.

Cells. 2019 May 10;8(5). pii: E441. doi: 10.3390/cells8050441.


Genetic Hierarchy of Acute Myeloid Leukemia: From Clonal Hematopoiesis to Molecular Residual Disease.

Martignoles JA, Delhommeau F, Hirsch P.

Int J Mol Sci. 2018 Dec 3;19(12). pii: E3850. doi: 10.3390/ijms19123850. Review.


Chronic myelogenous leukemia occurring in a chronic lymphocytic leukemia patient.

Beaud J, Modot T, Delhommeau F, Suner L.

Clin Case Rep. 2018 Jul 4;6(8):1655-1656. doi: 10.1002/ccr3.1572. eCollection 2018 Aug.


Myelodysplastic syndrome (MDS) with isolated trisomy 8: a type of MDS frequently associated with myeloproliferative features? A report by the Groupe Francophone des Myélodysplasies.

Drevon L, Marceau A, Maarek O, Cuccuini W, Clappier E, Eclache V, Cluzeau T, Richez V, Berkaoui I, Dimicoli-Salazar S, Bidet A, Vial JP, Park S, Vieira Dos Santos C, Kaphan E, Berthon C, Stamatoullas A, Delhommeau F, Abermil N, Braun T, Sapena R, Lusina D, Renneville A, Adès L, Raynaud S, Fenaux P.

Br J Haematol. 2018 Sep;182(6):843-850. doi: 10.1111/bjh.15490. Epub 2018 Jul 13.


Control in dormancy or eradication of cancer stem cells: Mathematical modeling and stability issues.

Djema W, Bonnet C, Mazenc F, Clairambault J, Fridman E, Hirsch P, Delhommeau F.

J Theor Biol. 2018 Jul 14;449:103-123. doi: 10.1016/j.jtbi.2018.03.038. Epub 2018 Apr 17.


TP53 mutations: the dawn of Shwachman clones.

Donadieu J, Delhommeau F.

Blood. 2018 Jan 25;131(4):376-377. doi: 10.1182/blood-2017-11-815431. No abstract available.


Sequential Conditioning with Thiotepa in T Cell- Replete Hematopoietic Stem Cell Transplantation for the Treatment of Refractory Hematologic Malignancies: Comparison with Matched Related, Haplo-Mismatched, and Unrelated Donors.

Duléry R, Ménard AL, Chantepie S, El-Cheikh J, François S, Delage J, Giannotti F, Ruggeri A, Brissot E, Battipaglia G, Malard F, Belhocine R, Sestili S, Vekhoff A, Delhommeau F, Reman O, Legrand O, Labopin M, Rubio MT, Mohty M.

Biol Blood Marrow Transplant. 2018 May;24(5):1013-1021. doi: 10.1016/j.bbmt.2018.01.005. Epub 2018 Jan 11.


Expression of CD94 by ex vivo-differentiated NK cells correlates with the in vitro and in vivo acquisition of cytotoxic features.

Hasmim M, Khalife N, Zhang Y, Doldur M, Visentin G, Terry S, Giron-Michel J, Tang R, Delhommeau F, Dulphy N, Bourhis JH, Louache F, Chouaib S.

Oncoimmunology. 2017 Jul 18;6(10):e1346763. doi: 10.1080/2162402X.2017.1346763. eCollection 2017.


Targeting primary acute myeloid leukemia with a new CXCR4 antagonist IgG1 antibody (PF-06747143).

Zhang Y, Saavedra E, Tang R, Gu Y, Lappin P, Trajkovic D, Liu SH, Smeal T, Fantin V, De Botton S, Legrand O, Delhommeau F, Pernasetti F, Louache F.

Sci Rep. 2017 Aug 4;7(1):7305. doi: 10.1038/s41598-017-07848-8.


Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism.

Farge T, Saland E, de Toni F, Aroua N, Hosseini M, Perry R, Bosc C, Sugita M, Stuani L, Fraisse M, Scotland S, Larrue C, Boutzen H, Féliu V, Nicolau-Travers ML, Cassant-Sourdy S, Broin N, David M, Serhan N, Sarry A, Tavitian S, Kaoma T, Vallar L, Iacovoni J, Linares LK, Montersino C, Castellano R, Griessinger E, Collette Y, Duchamp O, Barreira Y, Hirsch P, Palama T, Gales L, Delhommeau F, Garmy-Susini BH, Portais JC, Vergez F, Selak M, Danet-Desnoyers G, Carroll M, Récher C, Sarry JE.

Cancer Discov. 2017 Jul;7(7):716-735. doi: 10.1158/2159-8290.CD-16-0441. Epub 2017 Apr 17.


Precision and prognostic value of clone-specific minimal residual disease in acute myeloid leukemia.

Hirsch P, Tang R, Abermil N, Flandrin P, Moatti H, Favale F, Suner L, Lorre F, Marzac C, Fava F, Mamez AC, Lapusan S, Isnard F, Mohty M, Legrand O, Douay L, Bilhou-Nabera C, Delhommeau F.

Haematologica. 2017 Jul;102(7):1227-1237. doi: 10.3324/haematol.2016.159681. Epub 2017 Mar 16.


Reed Sternberg cell/lymphocyte rosettes in a bone marrow aspirate leading to the diagnosis of Hodgkin lymphoma.

Suner L, Gabignon C, Delhommeau F.

Br J Haematol. 2016 Nov;175(4):557. doi: 10.1111/bjh.14301. Epub 2016 Aug 24. No abstract available.


Genetic hierarchy and temporal variegation in the clonal history of acute myeloid leukaemia.

Hirsch P, Zhang Y, Tang R, Joulin V, Boutroux H, Pronier E, Moatti H, Flandrin P, Marzac C, Bories D, Fava F, Mokrani H, Betems A, Lorre F, Favier R, Féger F, Mohty M, Douay L, Legrand O, Bilhou-Nabera C, Louache F, Delhommeau F.

Nat Commun. 2016 Aug 18;7:12475. doi: 10.1038/ncomms12475.


Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia.

Boutzen H, Saland E, Larrue C, de Toni F, Gales L, Castelli FA, Cathebas M, Zaghdoudi S, Stuani L, Kaoma T, Riscal R, Yang G, Hirsch P, David M, De Mas-Mansat V, Delabesse E, Vallar L, Delhommeau F, Jouanin I, Ouerfelli O, Le Cam L, Linares LK, Junot C, Portais JC, Vergez F, Récher C, Sarry JE.

J Exp Med. 2016 Apr 4;213(4):483-97. doi: 10.1084/jem.20150736. Epub 2016 Mar 7.


Clonal history of a cord blood donor cell leukemia with prenatal somatic JAK2 V617F mutation.

Hirsch P, Mamez AC, Belhocine R, Lapusan S, Tang R, Suner L, Bories D, Marzac C, Fava F, Legrand O, Mohty M, Douay L, Delhommeau F.

Leukemia. 2016 Aug;30(8):1756-9. doi: 10.1038/leu.2016.31. Epub 2016 Mar 1. No abstract available.


Effect of mutation order on myeloproliferative neoplasms.

Delhommeau F.

N Engl J Med. 2015 May 7;372(19):1865. doi: 10.1056/NEJMc1503143. No abstract available.


JAK2V617F mRNA metabolism in myeloproliferative neoplasm cell lines.

Nauroy P, Delhommeau F, Baklouti F.

Blood Cancer J. 2014 Jun 27;4:e222. doi: 10.1038/bcj.2014.43. No abstract available.


Interest of cytogenetic and FISH evaluation for prognosis evaluation in 198 patients with acute myeloid leukemia in first complete remission in a single institution.

Hirsch P, Labopin M, Viguié F, Perot C, Isnard F, Mamez AC, Bilhou-Nabera C, Marzac C, Delhommeau F, Lapusan S, Marie JP, Mohty M, Legrand O.

Leuk Res. 2014 Aug;38(8):907-12. doi: 10.1016/j.leukres.2014.05.021. Epub 2014 Jun 4.


TET2 deficiency inhibits mesoderm and hematopoietic differentiation in human embryonic stem cells.

Langlois T, da Costa Reis Monte-Mor B, Lenglet G, Droin N, Marty C, Le Couédic JP, Almire C, Auger N, Mercher T, Delhommeau F, Christensen J, Helin K, Debili N, Fuks F, Bernard OA, Solary E, Vainchenker W, Plo I.

Stem Cells. 2014 Aug;32(8):2084-97. doi: 10.1002/stem.1718.


CXXC5 (retinoid-inducible nuclear factor, RINF) is a potential therapeutic target in high-risk human acute myeloid leukemia.

Astori A, Fredly H, Aloysius TA, Bullinger L, Mansat-De Mas V, de la Grange P, Delhommeau F, Hagen KM, Récher C, Dusanter-Fourt I, Knappskog S, Lillehaug JR, Pendino F, Bruserud Ø.

Oncotarget. 2013 Sep;4(9):1438-48.


Applying ecological and evolutionary theory to cancer: a long and winding road.

Thomas F, Fisher D, Fort P, Marie JP, Daoust S, Roche B, Grunau C, Cosseau C, Mitta G, Baghdiguian S, Rousset F, Lassus P, Assenat E, Grégoire D, Missé D, Lorz A, Billy F, Vainchenker W, Delhommeau F, Koscielny S, Itzykson R, Tang R, Fava F, Ballesta A, Lepoutre T, Krasinska L, Dulic V, Raynaud P, Blache P, Quittau-Prevostel C, Vignal E, Trauchessec H, Perthame B, Clairambault J, Volpert V, Solary E, Hibner U, Hochberg ME.

Evol Appl. 2013 Jan;6(1):1-10. doi: 10.1111/eva.12021. Epub 2012 Nov 16.


Clonal architecture of chronic myelomonocytic leukemias.

Itzykson R, Kosmider O, Renneville A, Morabito M, Preudhomme C, Berthon C, Adès L, Fenaux P, Platzbecker U, Gagey O, Rameau P, Meurice G, Oréar C, Delhommeau F, Bernard OA, Fontenay M, Vainchenker W, Droin N, Solary E.

Blood. 2013 Mar 21;121(12):2186-98. doi: 10.1182/blood-2012-06-440347. Epub 2013 Jan 14.


Role of TET2 mutations in myeloproliferative neoplasms.

Pronier E, Delhommeau F.

Curr Hematol Malig Rep. 2012 Mar;7(1):57-64. doi: 10.1007/s11899-011-0108-8.


The cell cycle regulator CDC25A is a target for JAK2V617F oncogene.

Gautier EF, Picard M, Laurent C, Marty C, Villeval JL, Demur C, Delhommeau F, Hexner E, Giraudier S, Bonnevialle N, Ducommun B, Récher C, Laurent G, Manenti S, Mansat-De Mas V.

Blood. 2012 Feb 2;119(5):1190-9. doi: 10.1182/blood-2011-01-327742. Epub 2011 Nov 7.


Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors.

Pronier E, Almire C, Mokrani H, Vasanthakumar A, Simon A, da Costa Reis Monte Mor B, Massé A, Le Couédic JP, Pendino F, Carbonne B, Larghero J, Ravanat JL, Casadevall N, Bernard OA, Droin N, Solary E, Godley LA, Vainchenker W, Plo I, Delhommeau F.

Blood. 2011 Sep 1;118(9):2551-5. doi: 10.1182/blood-2010-12-324707. Epub 2011 Jul 6.


TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis.

Quivoron C, Couronné L, Della Valle V, Lopez CK, Plo I, Wagner-Ballon O, Do Cruzeiro M, Delhommeau F, Arnulf B, Stern MH, Godley L, Opolon P, Tilly H, Solary E, Duffourd Y, Dessen P, Merle-Beral H, Nguyen-Khac F, Fontenay M, Vainchenker W, Bastard C, Mercher T, Bernard OA.

Cancer Cell. 2011 Jul 12;20(1):25-38. doi: 10.1016/j.ccr.2011.06.003. Epub 2011 Jun 30.


New mutations and pathogenesis of myeloproliferative neoplasms.

Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA.

Blood. 2011 Aug 18;118(7):1723-35. doi: 10.1182/blood-2011-02-292102. Epub 2011 Jun 7. Review.


Extent of hematopoietic involvement by TET2 mutations in JAK2V⁶¹⁷F polycythemia vera.

Swierczek SI, Yoon D, Bellanné-Chantelot C, Kim SJ, Saint-Martin C, Delhommeau F, Najman A, Prchal JT.

Haematologica. 2011 May;96(5):775-8. doi: 10.3324/haematol.2010.029678. Epub 2011 Jan 27.


The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues.

Van Etten RA, Koschmieder S, Delhommeau F, Perrotti D, Holyoake T, Pardanani A, Mesa R, Green T, Ibrahim AR, Mughal T, Gale RP, Goldman J.

Haematologica. 2011 Apr;96(4):590-601. doi: 10.3324/haematol.2010.035675. Epub 2011 Jan 17. Review.


Nonsense-mediated mRNA decay (NMD) blockage promotes nonsense mRNA stabilization in protein 4.1R deficient cells carrying the 4.1R Coimbra variant of hereditary elliptocytosis.

Morinière M, Delhommeau F, Calender A, Ribeiro L, Delaunay J, Baklouti F.

Blood Cells Mol Dis. 2010 Dec 15;45(4):284-8. doi: 10.1016/j.bcmd.2010.08.011. Epub 2010 Sep 21.


Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells.

Kiladjian JJ, Massé A, Cassinat B, Mokrani H, Teyssandier I, le Couédic JP, Cambier N, Almire C, Pronier E, Casadevall N, Vainchenker W, Chomienne C, Delhommeau F; French Intergroup of Myeloproliferative Neoplasms (FIM).

Leukemia. 2010 Aug;24(8):1519-23. doi: 10.1038/leu.2010.120. Epub 2010 Jun 3. No abstract available.


Primary plasma cell leukemia mimicking an adult T-cell leukemia-lymphoma: a case report.

Delhommeau F, Huguet S, Gachet J, van den Akker J, Lagrange M.

Acta Cytol. 2010 Mar-Apr;54(2):187-9.


Molecular aspects of myeloproliferative neoplasms.

Delhommeau F, Jeziorowska D, Marzac C, Casadevall N.

Int J Hematol. 2010 Mar;91(2):165-73. doi: 10.1007/s12185-010-0530-z. Epub 2010 Feb 27. Review.


Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm.

Beer PA, Delhommeau F, LeCouédic JP, Dawson MA, Chen E, Bareford D, Kusec R, McMullin MF, Harrison CN, Vannucchi AM, Vainchenker W, Green AR.

Blood. 2010 Apr 8;115(14):2891-900. doi: 10.1182/blood-2009-08-236596. Epub 2009 Dec 11.


[Mutations in TET2 in myeloid cancers].

Bernard OA, Delhommeau F, Fontenay M, Vainchenker W.

Med Sci (Paris). 2009 Oct;25(10):785-8. doi: 10.1051/medsci/20092510785. French. No abstract available.


Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms.

Saint-Martin C, Leroy G, Delhommeau F, Panelatti G, Dupont S, James C, Plo I, Bordessoule D, Chomienne C, Delannoy A, Devidas A, Gardembas-Pain M, Isnard F, Plumelle Y, Bernard O, Vainchenker W, Najman A, Bellanné-Chantelot C; French Group of Familial Myeloproliferative Disorders.

Blood. 2009 Aug 20;114(8):1628-32. doi: 10.1182/blood-2009-01-197525. Epub 2009 Jun 29.


Mutation in TET2 in myeloid cancers.

Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Massé A, Kosmider O, Le Couedic JP, Robert F, Alberdi A, Lécluse Y, Plo I, Dreyfus FJ, Marzac C, Casadevall N, Lacombe C, Romana SP, Dessen P, Soulier J, Viguié F, Fontenay M, Vainchenker W, Bernard OA.

N Engl J Med. 2009 May 28;360(22):2289-301. doi: 10.1056/NEJMoa0810069.


TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis.

Tefferi A, Pardanani A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Gangat N, Finke CM, Schwager S, Mullally A, Li CY, Hanson CA, Mesa R, Bernard O, Delhommeau F, Vainchenker W, Gilliland DG, Levine RL.

Leukemia. 2009 May;23(5):905-11. doi: 10.1038/leu.2009.47. Epub 2009 Mar 5.


The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity.

James C, Mazurier F, Dupont S, Chaligne R, Lamrissi-Garcia I, Tulliez M, Lippert E, Mahon FX, Pasquet JM, Etienne G, Delhommeau F, Giraudier S, Vainchenker W, de Verneuil H.

Blood. 2008 Sep 15;112(6):2429-38. doi: 10.1182/blood-2008-02-137877. Epub 2008 Jul 8.


Human telomerase is regulated by erythropoietin and transforming growth factor-beta in human erythroid progenitor cells.

Prade-Houdellier N, Frébet E, Demur C, Gautier EF, Delhommeau F, Bennaceur-Griscelli AL, Gaudin C, Martinel V, Laurent G, Mansat-De Mas V, Beyne-Rauzy O.

Leukemia. 2007 Nov;21(11):2304-10. Epub 2007 Aug 23.


Telomere shortening and associated chromosomal instability in peripheral blood lymphocytes of patients with Hodgkin's lymphoma prior to any treatment are predictive of second cancers.

M'kacher R, Bennaceur-Griscelli A, Girinsky T, Koscielny S, Delhommeau F, Dossou J, Violot D, Leclercq E, Courtier MH, Béron-Gaillard N, Assaf E, Ribrag V, Bourhis J, Feneux D, Bernheim A, Parmentier C, Carde P.

Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):465-71. Epub 2007 Apr 6.


The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera.

Dupont S, Massé A, James C, Teyssandier I, Lécluse Y, Larbret F, Ugo V, Saulnier P, Koscielny S, Le Couédic JP, Casadevall N, Vainchenker W, Delhommeau F.

Blood. 2007 Aug 1;110(3):1013-21. Epub 2007 Mar 27.


Oncogenic mechanisms in myeloproliferative disorders.

Delhommeau F, Pisani DF, James C, Casadevall N, Constantinescu S, Vainchenker W.

Cell Mol Life Sci. 2006 Dec;63(24):2939-53. Review.


Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis.

Delhommeau F, Dupont S, Tonetti C, Massé A, Godin I, Le Couedic JP, Debili N, Saulnier P, Casadevall N, Vainchenker W, Giraudier S.

Blood. 2007 Jan 1;109(1):71-7. Epub 2006 Sep 5.


Oncogenic kinases of myeloproliferative disorders induce both protein synthesis and G1 activators.

Lelièvre H, Cervera N, Finetti P, Delhommeau F, Vainchenker W, Bertucci F, Birnbaum D.

Leukemia. 2006 Oct;20(10):1885-8. Epub 2006 Aug 10. No abstract available.


Supplemental Content

Loading ...
Support Center